Macomics

Executive Summary

Macomics is a privately held macrophage drug discovery company headquartered in Edinburgh, United Kingdom, founded in 2019. The company is pioneering first-in-class therapeutics that directly modulate macrophage activity to address diseases with high unmet medical need, including oncology, fibrosis, and inflammatory conditions. Macomics leverages its proprietary ENIGMAC™ platform to systematically identify novel macrophage targets and generate genetic models of disease, enabling a precision approach to macrophage biology. The platform integrates advanced genomics, bioinformatics, and functional validation to uncover targets that are selectively expressed in disease-associated macrophages, reducing the risk of on-target, off-tissue toxicity. By focusing on the myeloid arm of the immune system, Macomics is positioned to develop transformative therapies that complement T cell-centric immunotherapies. The company's lead programs are in preclinical development, targeting both immuno-oncology and immuno-inflammatory indications. While Macomics has not disclosed specific financial details or clinical stage, its platform-driven strategy and focus on a validated but underexploited cell type provide a differentiated approach in the biotech landscape. The company is well-suited for partnerships with larger pharma seeking novel macrophage-modulating agents.

Upcoming Catalysts (preview)

• Q2 2027Lead Program IND Filing or Entering Clinic30% success
• Q4 2026Strategic Partnership or Licensing Deal45% success
• Q3 2026Series B or Significant Funding Round60% success